Type 2 Diabetes
Research findings from J.E. Foley et al update understanding of type 2 diabetes
Published in Diabetes Week, March 1st, 2010
According to a study from the United States, "This report is part of the overall evaluation of using vildagliptin in the treatment of type 2 diabetes. Here the results of a multi-center, double-blind, randomized, active-controlled Study designed to compare the efficacy and safety of two years of monotherapy with vildagliptin 50 mg bid and gliclazide up to 320 mg/day in drug-naive patients with type 2 diabetes are reported."
"A total of 546 patients were randomized and similar to 74% of patients completed the Study in each group. HbA(1c) values were slightly higher in the gliclazide group (HbA(1c) of 8.7 +/- 0.1 % vs. 8.5 +/- 0.1 % in the vildagliptin group). The mean...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
Source: Diabetes Week (2010-03-01)
More Articles from Diabetes Week
- Massachusetts General Hospital
Rates of childhood obesity, chronic health problems increase, but conditions may not persist - McMaster University
Researchers develop dietary formula that maintains youthful function into old age - Trinity College Dublin
New research on type 2 diabetes could benefit young adults with the condition - Alcoholism
Reports by C. Merlo and co-researchers describe recent advances in alcoholism - Angiotensins
New data from Capital Medical University illuminate research in angiotensins - Atherosclerosis
Reports outline atherosclerosis study findings from Wake Forest University - More from this issue of Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
